Loading...
Images of Erik Depla
(0 from 0 )1
0
0
News
64 Million RSV Infections Per Year: Perhaps Alpaca Nanobodies ...www.labiotech.eu › News and Trends
www.labiotech.eu
18-Dec · Abynx's Nanobody platform uses Camelidae (Alpaca/Llama) antibodies due to theri smaller size (Source: Ablynx Presentation by Erik Depla, ...
Network Profiles
LinkedIn: Erik Depla | LinkedIn
Erik Deplas berufliches Profil anzeigen LinkedIn ist das weltweit größte berufliche Netzwerk, das Fach- und Führungskräften wie Erik Depla dabei hilft, interne ...
Interests
[PPT]
www.jbc.org
... Hidenao Toyoda, Akiko Kinoshita-Toyoda, Toshihiko Toida, Toin H. van Kuppevelt, Erik Depla, Fritz von Weizsäcker, Hubert E. Blum, Thomas F. Baumert.
Business Profiles
Erik DEPLA | Vlaams Instituut voor Biotechnologie, Gent | VIBwww.researchgate.net › Vlaams Instituut voor Biotechnologie
www.researchgate.net
Erik DEPLA, Expert Discovery Biology | Cited by | of Vlaams Instituut voor Biotechnologie, Gent (VIB) | Read 82 publications | Contact Erik DEPLA.
patentbuddy: Erik Depla
PHARMEXA INC.
Employees
About Us - Orionis Biosciencesorionisbio.com › about-us
orionisbio.com
Management Team · Andrew Littlehale, MBA · James Kyranos, Ph.D. · Edward Suh, Ph.D. · Erik Depla, Ph.D. · Sam Lievens, Ph.D.
Books & Literature
Immunogenicity and Tolerability of Intradermal Administrationwww.tandfonline.com › doi › pdf
www.tandfonline.com
trial: Frédéric Clement, Yvonne Gijbels, Andrea Verwulgen, Erik Depla,. Sofie Priem, and Marie-Ange Buyse. We thank Drs Isabelle Colle, André.
Desmin expressing nonhematopoietic liver cells during rat liver ...onlinelibrary.wiley.com › doi › abs
onlinelibrary.wiley.com
Erik Depla,. Erik Depla. Department of Internal Medicine, Laboratory of Hepatology, University of Leuven, Leuven, Belgium.
Annexins: Biological Importance and Annexin-Related Pathologiesbooks.google.co.in › books
books.google.co.in
... England Chapter 5 Erik Depla Innogenetics NV Gent , Belgium Chapter 17 Rosario Donato Department of Experimental Medicine and Biochemical Sciences ...
Frontiers in Viral Hepatitisbooks.google.co.in › books
books.google.co.in
Perspectives in HCV vaccine development Introduction ERIK DEPLA Innogenetics , N.V. , Industriepark Zwijnaarde 7 , Box 4 , Ghent B , Belgium The ...
Related Documents
Calcium-dependent phospholipid- (and membrane-) binding proteinspubs.acs.org › doi › abs
pubs.acs.org
06-Sept · ... Sandra De Meyer, Zuojiong Gong, Erik Depla, Geert Maertens, Sing Hiem Yap Erik Depla, Ann Soumillion, Johan Fevery, Sing-Hiem Yap.
Journal of General Virology (2002), 83, 1673– Printed in Great ...citeseerx.ist.psu.edu › viewdoc › summary
citeseerx.ist.psu.edu
by Saadia Bichr , Rosanna Rende-fournier , Giovanna Vona , Ana-maria Yamamoto , Erik Depla , Geert Maertens , Christian Bre Chot ...
Clearance of Genotype 1b Hepatitis C Virus in Chimpanzees in the ...academic.oup.com › jid › article-abstract
academic.oup.com
Erik Depla,. Erik Depla. 2Innogenetics N.V, Industriepark Zwijnaarde, Ghent, Belgium. Search for other works by this author on:.
[PDF] 1 MARCH2018student.vub.be › sites › vub › files › poster_drug_discovery
student.vub.be
01-Mar · Erik Depla. Orionis Biosciences | BE. Bert Schepens. VIB-UGent Center for Medical Biotechnology | BE. Evelien Smits.
Scientific Publications
Binding of Hepatitis C Virus-Like Particles Derived from Infectious ...www.ncbi.nlm.nih.gov › pmc › articles › PMC
www.ncbi.nlm.nih.gov
Sabine Wellnitz,1 Bettina Klumpp,1 Heidi Barth,1 Susumu Ito,2 Erik Depla,3 Jean Dubuisson,4 Hubert E. Blum,1 and Thomas F. Baumert1,* ...
Vol. 204, No. 6, 15 September JSTORwww.jstor.org › stable
www.jstor.org
Babs E. Verstrepen, Erik Depla, Christine S. Rollier, Gwenny Mares, Joost A. R. Drexhage, Sofie Priem, Ernst J. Verschoor, Gerrit Koopman, ...
Hepatitis C Virus Targets DC-SIGN and L-SIGN To Escape NCBIwww.ncbi.nlm.nih.gov › pmc › articles › PMC
www.ncbi.nlm.nih.gov
Irene S. Ludwig,1 Annemarie N. Lekkerkerker,1 Erik Depla,2 Fons Bosman,2 René J. P. Musters,3 Stany Depraetere,2 Yvette van Kooyk,1 and Teunis B. H. ...
Thank you to Virology Journal's peer reviewers in | Virology...
virologyj.biomedcentral.com
Erik Depla. Belgium. Klaus Depner. Germany. Moutaz Derbala. Qatar. Daniel Desmecht. Belgium. Ulrich Desselberger. UK. Joanne Devlin.
Publications
Clearance of Genotype 1b Hepatitis C Virus in BioMedSearch
www.biomedsearch.com
Babs E. Verstrepen,1 Erik Depla,2,a Christine S. Rollier,1,b Gwenny Mares,2,a Joost A. R. Drexhage,1 Sofie Priem,2,a Ernst. J. Verschoor,1 Gerrit Koopman,1 ...
Miscellaneous
EP A1 - Modified hepatitis C virus (HCV) NS5 - Googlewww.google.com › patents
www.google.com
Application number: EP ; Other languages: German (de) · English (en) · French (fr); Inventor: Erik Depla: Geert Maertens: Fons Bosman ...
Expression of core-glycosylated HCV envelope proteins in yeastwww.google.co.ug › patents
www.google.co.ug
Application number: US ,578; Other versions: US A1 (en; Inventor: Fons Bosman: Erik Depla: Geert Deschamps: Erwin Sablon: Isabelle Samson ...
Peptides for inducing a CTL and/or HTL response to hepatitis C viruspatents.google.com › patent
patents.google.com
Application number: US ,487; Inventor: Marie-Ange Buyse: Geert Maertens: Erik Depla: Ignace Lasters: Johan Desmet: Denise Baker: Robert Chesnut: Mark ...
Erik Depla - VIB Conferenceswww.vibconferences.be › speaker › erik-depla
www.vibconferences.be
Home>; Erik Depla. Depla Erik - Profile picture - ©IneDehandschutter. Erik Depla. Orionis Biosciences, BE. More information. Visit Erik Depla's page ...
Erik Depla email address & phone number | Orionis Biosciences ...rocketreach.co › erik-depla-email_
rocketreach.co
Get Erik Depla's email address () and phone number () at RocketReach. Get 5 free searches.
Depla Erik Company Profile | Destelbergen, EAST-FLANDERS ...www.dnb.com › ... › BELGIUM › EAST-FLANDERS › DESTELBERGEN
www.dnb.com
Key Principal: Erik Depla See more contacts. Industry: Business Support Services , Architectural, Engineering, and Related Services , Business, Professional ...
(PDF) A candidate vaccine based on the hepatitis C E1 proteinwww.academia.edu › A_candidate_vaccine_based_on_the_hepatitis_C_E1...
www.academia.edu
... Erik Depla b , Frank Hulstaert b,∗ , Leen Tobback b , Stéphanie Dincq b , Jaques Desmet c , Isabelle Desombere a , Geert Maertens b a Center for ...
Barbara Rehermann: H-index & Awards - Academic Profileresearch.com › Immunology
research.com
Akinobu Takaki;Manfred Wiese;Geert Maertens;Erik Depla. Nature Medicine (2000) Citations. A variant upstream of IFNL3 (IL28B) creating a new interferon ...
Bibliographic Data - Application - Patent Center - USPTOpatentcenter.uspto.gov
patentcenter.uspto.gov
Inventors · Erik Depla. Destelbergen (BE) · Catelijne Stortelers. Gent (BE) ...
Biologics For Autoimmune Pegs Summitwww.pegsummit.com › Biologics-for-Autoimmune
www.pegsummit.com
Erik Depla, Ph.D. Expert, Discovery Biology, VIB. IL-33 and TSLP are two cytokines that are released from epithelial surfaces and which control the fate of ...
Directoryslastranslatingresearchidea2016.sched.com › directory › attendees
slastranslatingresearchidea2016.sched.com
Erik Depla. VIB. Expert Discovery Biology. KV · Kris Ver Donck. Confluence Consulting. Sr. Advisor. avatar for Heidrun Dorsch · Heidrun Dorsch. Bayer.
Download presentations of the Brussels conference Eufemedwww.eufemed.eu › download-presentations-of-the-brussels-conference-2015
www.eufemed.eu
To what extent are “challenge agents” acceptable? Jan de Hoon, Belgium. Non-clinical and early clinical development of nanobodies. Erik Depla, Belgium ...
Expression of interferon-γ receptor in normal and pathological ...www.journal-of-hepatology.eu › article › fulltext
www.journal-of-hepatology.eu
Erik Depla. Erik Depla. Affiliations. Laboratory of Biochemistry, Catholic University of Leuven, Leuven, Belgium. Search for articles by this author.
Generation and Characterization of ALX-0171, a Potent Novel ...pure.qub.ac.uk › publications › generation-and-characterization-of-alx
pure.qub.ac.uk
... Pedro A. Piedra, Brian E. Gilbert, Vicente Mas, Andrena Millar, Ultan F. Power, Catelijne Stortelers, Koen Allosery, Jose A. Melero, Erik Depla.
Hepatitis Monthly | Issue 7 (3) - Brieflandsbrieflands.com › journals › hepatitis-monthly › issue
brieflands.com
seyed Jazayeri, Edward Doman, Erik Depla, William Carman *. |. Final Published. Research Article. Screening for Hepatocellular Carcinoma in Chronic Carriers ...
High Throughput Combinatorial Formatting of PcrV Nanobodies for ...europepmc.org › article › pmc › pmc
europepmc.org
... Rob Van Hegelsom, Rita Figueirido,2 Jeroen Noens, Søren Steffensen, Thomas Stöhr,3 Willem Van de Velde, Erik Depla,4 and Bruno Dombrecht5 ...
Host cell responses induced by hepatitis C virus binding. - HAL-Insermwww.hal.inserm.fr › inserm
www.hal.inserm.fr
... Timmer 2 Winfried V. Kern 1 Johannes Donauer 3 Marcel Geyer 3 Gerd Walz 3 Erik Depla 4 Fritz von Weizsäcker 1 Hubert E. Blum 1 Thomas F. Baumert 1, 5, *
Infectious hepatitis C virus pseudo-particles containing functional E1 ...www.xnxbz.net › xbnlkjdxzr › reader › view_reference
www.xnxbz.net
[19]、, Jean-Christophe Meunier, Rodney S. Russell, Vera Goossens, Sofie Priem, Hugo Walter, Erik Depla, Ann Union, Kristina N. Faulk, Jens Bukh, ...
Modified HEPATITIS C VIRUS (HCV) NS5 - MyScienceWorkwww.mysciencework.com › patent › show
www.mysciencework.com
... HEPATITIS C VIRUS (HCV) NS EP A1 - EPO. Application May 28, Publication Dec 01, Erik Depla Geert Maertens Fons Bosman ...
Neutralizing Host Responses in Hepatitis C Virus Infection Target ...www.gastrojournal.org › article › pdf
www.gastrojournal.org
ANN UNION,§§ ERIK DEPLA,§§ ANIA OWSIANKA, ARVIND H. PATEL, CATHERINE SCHUSTER,‡,§. FRANÇOISE STOLL–KELLER,‡,§ MICHEL DOFFOËL,¶¶ MARLÈNE DREUX,¶,#,** and ...
sorted by relevance / date